The administration of candesartan in the CHARM trial (Candesartan in Heart Failure–assessment of reduction in mortality and morbidity) in patients with CHF who did not tolerate ACE inhibitors led to a 23% reduction in cardiovascular mortality and hospital days [65]. This evidence concerns the gene ACE and heart failure.